Full Text View
Tabular View
No Study Results Posted
Related Studies
The Effects of Modafinil on Waking Function and on Sleep in Individuals With Primary Insomnia
This study has been completed.
Study NCT00124384   Information provided by University of Rochester
First Received: July 25, 2005   Last Updated: April 22, 2008   History of Changes

July 25, 2005
April 22, 2008
January 2005
August 2007   (final data collection date for primary outcome measure)
Change in sleep latency, wake after sleep onset, sleep efficiency; efficacy of modafinil and the combination of modafinil and CBT-I on previously mentioned outcome measures
Change in sleep latency, wake after sleep onset, sleep efficiency; efficacy of modafinil and the combination of modfinil and CBT-I on previously mentioned outcome measures
Complete list of historical versions of study NCT00124384 on ClinicalTrials.gov Archive Site
Long term (3 months) effects of treatment
Long term (3 months)effects of treatment
 
The Effects of Modafinil on Waking Function and on Sleep in Individuals With Primary Insomnia
Phase 4 Study of the Effects of Modafinil on Waking Function and on Sleep in Individuals With Primary Insomnia

This study examines how treatment with the drug modafinil, by itself or in combination with cognitive behavioral treatment for insomnia (CBT-I), may improve daytime functioning and/or diminish the severity of insomnia.

Our primary goal is to undertake a 2nd study evaluating whether Modafinil, alone or in combination with behavioral treatment for insomnia, will improve subjects' sleep continuity and/or self report daytime function.

METHODS AND PROCEDURES

Schedule for Procedures.

Screening interview Sleep over night in our lab for one night 8 weeks of either behavioral or psychological therapy for insomnia 3 month post therapy follow up (two weeks of sleep diaries and one lab visit)

40 patients aged 25-80 with insomnia. All subjects will have a stable sleep/wake schedule with a preferred sleep phase between 10:00 PM and 8:00 AM. The age range is restricted to 1) minimize circadian rhythm influences on the diagnoses of Psychophysiological insomnia, 2) to increase our ability to recruit medically healthy sample, and 3) increase sample homogeneity.

All subjects will meet diagnostic criteria for Psychophysiological Insomnia according to the International Classification of Sleep Disorders (ICSD). Criteria are: the complaint of insomnia and impaired daytime function; an indication of learned sleep-preventing associations and somatized tension; active help seeking. The complaint of disturbed sleep will have one or more of the following characteristics: >30 minutes to fall asleep and/or >2 awakenings per night of >15 minutes duration and/or wake after sleep onset time of > 30 minutes, problem frequency >4 nights/ week, and problem duration >6 months. In addition, all subjects will complain of fatigue and/or sleepiness at intake.

Treatment.

Regardless of group assignment, all subjects will 1) wear an actiwatch, 2) be seen on an individual basis for 8 weeks. Session length will be held constant and all patients will be seen by the same therapist (Wilfred Pigeon, PhD). Backup support will be provided by the Principal Investigator (Michael Perlis, PhD) or by the Clinic's Nurse Practitioner (Carla Jungquist, MSN) and 3) complete daily sleep diaries for duration of the study (from study intake until study end [8 weeks]).

Phase IV
Interventional
Treatment, Randomized, Single Blind, Placebo Control, Parallel Assignment, Efficacy Study
Primary Insomnia
  • Behavioral: CBT-I
  • Drug: modafinil
 
Perlis ML, Smith MT, Orff H, Enright T, Nowakowski S, Jungquist C, Plotkin K. The effects of modafinil and cognitive behavior therapy on sleep continuity in patients with primary insomnia. Sleep. 2004 Jun 15;27(4):715-25.

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
40
August 2007
August 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • 40 patients aged 25 with insomnia, will be recruited over a 3-6 month interval.
  • All subjects will have a stable sleep/wake schedule with a preferred sleep phase between 10:00 PM and 8:00 AM.
  • Must live in the Greater Rochester NY area
  • All subjects will meet diagnostic criteria for Psychophysiological Insomnia according to the International Classification of Sleep Disorders (ICSD). Criteria are: the complaint of insomnia and impaired daytime function; an indication of learned sleep-preventing associations and somatized tension; active help seeking. The complaint of disturbed sleep will have one or more of the following characteristics: >30 minutes to fall asleep and/or >2 awakenings per night of >15 minutes duration and/or wake after sleep onset time of > 30 minutes, problem frequency >4 nights/ week, and problem duration >6 months. In addition, all subjects will complain of fatigue and/or sleepiness at intake.

Exclusion Criteria:

  • As above
Both
25 Years to 80 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00124384
Michael L. Perlis, PhD., University of Rochester
C1538a/6029/IN/US, RSRB # 10306
University of Rochester
Cephalon
Principal Investigator: Michael Perlis, PhD University of Rochester Sleep Research Lab
University of Rochester
April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP